Company Encyclopedia
View More
name
WUZHOU MEDICAL
301234.SZ
Anhui Hongyu Wuzhou Medical Manufacturer Co.,LTD. engages in the research, development, production, and sale of disposable sterile infusion medical devices in China. It offers disposable syringes, infusion (blood) devices, puncture needles, hypodermic needles, blood collection needles and sets, conventional syringes, and insulin syringes and pen needles, as well as infusion, blood administration, burette, and scalp vein sets. The company also exports its products to approximately 80 countries.
337.57 B
301234.SZMarket value -Rank by Market Cap -/-

Financial Score

27/12/2025 Update
B
Health Care SuppliesIndustry
Industry Ranking15/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.18%C
    • Profit Margin5.03%C
    • Gross Margin15.05%D
  • Growth ScoreC
    • Revenue YoY4.04%C
    • Net Profit YoY-40.47%D
    • Total Assets YoY1.02%C
    • Net Assets YoY0.50%C
  • Cash ScoreB
    • Cash Flow Margin1989.12%A
    • OCF YoY4.04%C
  • Operating ScoreC
    • Turnover0.56C
  • Debt ScoreA
    • Gearing Ratio12.32%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    WUZHOU MEDICAL released its performance for the first three quarters, with a net profit attributable to the parent company of 18.5094 million yuan, a year-on-year decrease of 46.09%

    According to the Zhitong Finance APP, WUZHOU MEDICAL released its third-quarter report for 2025. In the first three quarters, the company achieved operating revenue of 345 million yuan, a year-on-year increase of 0.82%. The net profit attributable to shareholders of the listed company was 18.5094 million yuan, a year-on-year decrease of 46.09%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 14.8165 million yuan, a year-on-year decrease of 45.30%

    Zhitong·
    SZ
    301234
    -1.61%
    Zhitong·
    SZ
    301234
    -1.61%

    WUZHOU MEDICAL: Some shareholders plan to reduce their holdings by 1.86% of the company's shares

    WUZHOU MEDICAL announced that some shareholders plan to reduce their holdings in the company, totaling a reduction of 1.86%. Taihu Honghui Medical Management Partnership, which holds 5.2388%, along with its supervisor and deputy general manager, plan to reduce their holdings by 1,068,705 shares, 127,500 shares, and 69,050 shares, respectively, with the total reduction accounting for 1.8606% of the company's total share capital

    Zhitong·
    SZ
    301234
    -1.61%
    Zhitong·
    SZ
    301234
    -1.61%

    The medical device sector saw a short-term surge, with JG Development hitting the daily limit

    The medical device sector saw a short-term surge, with JG Development hitting the limit up, BIOLIGHT rising over 10%, and Improve Medical, Tianyi Medical, DIRUI, Guanhao Biotech, and Chunli Medical also following suit

    Zhitong·
    SZ
    300238
    -1.33%
    SH
    688236
    -1.82%
    HK
    01858
    +0.93%
    Zhitong·
    SZ
    300238
    -1.33%
    SH
    688236
    -1.82%
    HK
    01858
    +0.93%

    WUZHOU MEDICAL: Shareholder Zhang Hongyu and his concerted actors' shareholding ratio decreased to 15%

    WUZHOU MEDICAL announced that the concerted action agreement of the information disclosure obligor Zhang Hongyu has expired and will not be renewed, and the shares held in the company will no longer be consolidated. After this equity change, Zhang Hongyu and his concerted actors hold a total of 10.2 million shares, accounting for 15% of the company's total share capital. This equity change will not lead to changes in the company's main business, will not affect the independence of the company's personnel, financial independence, and asset integrity, will not have a significant impact on the company's financial condition, nor will it have a significant impact on the company's governance structure and production operations

    Zhitong·
    SZ
    301234
    -1.61%
    Zhitong·
    SZ
    301234
    -1.61%

    WUZHOU MEDICAL: The "Joint Action Agreement" of the controlling shareholder and actual controller has expired and terminated, with Huang Fan becoming the new actual controller

    WUZHOU MEDICAL announced that the "Consistent Action Agreement" signed by the company's controlling shareholders and actual controllers Huang Fan, Xiang Bingyi, and Zhang Hongyu will not be renewed after its expiration on July 5, 2025, and the tripartite consistent action relationship will be terminated. This change in equity does not involve a change in the number of shares but results in a change in the company's control, with Huang Fan becoming the new actual controller of the company. After the agreement expires, Huang Fan, Xiang Bingyi, and Zhang Hongyu will independently exercise their rights as shareholders and directors and continue to support the company's long-term stable development

    Zhitong·
    SZ
    301234
    -1.61%
    Zhitong·
    SZ
    301234
    -1.61%
    © 2025 Longbridge｜Disclaimer